Category: Azithromycin

Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2

Posted on | Posted on John Murphy | Leave a Comment on Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2

Patricia Sequeira Rodriguez, Rafael Santana Ortiz,at. al.Otolaryngol 2023: 2023.  doi:  10.1016/j.xocr.2023.100510, PMCID: PMC9850639,PMID: 3669145 Abstract About the neurological manifestations of COVID-19, smell impairment with some distortion or parosmia is currently one of the longest-lasting post-covid sequelae affecting many young adults around the world, we present a case of a 25yo patient that after the COVID-19 infection initiates with […]

Hydroxychloroquine Reduces COVID-19 Mortality, Study Finds

Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine Reduces COVID-19 Mortality, Study Finds

OCT 13, 2023 Authored by Zachary Stieber via The Epoch Times  People who took hydroxychloroquine in combination with another drug while hospitalized with COVID-19 were less likely to die than those who didn’t, according to a new study. Hydroxychloroquine, which is widely used against malaria and arthritis, was given to hundreds of patients hospitalized with COVID-19 […]

Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak

Posted on | Posted on John Murphy | Leave a Comment on Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak

Claudio Conforti, 1 Roberta Giuffrida, 2 Iris Zalaudek, 1 and Nicola Di Meo 1 Dermatol Ther. 2020 Jul-Aug; 33(4): e13437. Published online 2020 May 15. doi: 10.1111/dth.13437 PMCID: PMC7235480PMID: 32314492 The recent SARS‐CoV‐2 pandemic, for which there is still no approved vaccine, required research into effective treatments to limit, contain, and improve the outcome of affected patients. 1 , 2 Symptoms of coronavirus disease 19 (COVID‐19) range from mild to severe […]